ArticleInternational journal of general medicine2025
Clinical Value of APRI and FIB-4 on Bleeding Risk and 30-Day Prognosis in Patients with Liver Cirrhosis Complicated with Esophagogastric Varices.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Off-Hours Endoscopic Management and Clinical Outcomes in Acute Esophageal Variceal Bleeding: A Real-World Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Evaluation of Prognosis in Cirrhotic Patients with Esophageal Variceal Bleeding Using Non-Invasive Scores.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the clinical utility of aspartate transaminase-to-platelet ratio index (APRI) and fibrosis-4 index (FIB-4) in predicting both the risk and 30-day prognosis of esophagogastric variceal bleeding (EGVB) in patients with liver cirrhosis. Methods: In this retrospective cohort study, 231 cirrhotic patients (92 with EGVB and 139 controls) were randomly allocated to derivation (n=162) and validation (n=69) cohorts (7:3 ratio). Independent predictors of EGVB were identified through multivariate regression analysis, and a nomogram model was developed. Model performance was evaluated through internal validation assessing discrimination (ROC analysis), calibration (calibration curves), and clinical utility (decision curve analysis). The bleeding cohort was stratified into non-survivors (n=31) and survivors (n=61), with multivariate COX regression and Kaplan-Meier analyses examining associations between APRI/FIB-4 and 30-day mortality. Results: APRI, FIB-4, and WBC emerged as independent EGVB risk factors ( Conclusion: APRI, FIB-4, and WBC serve as independent EGVB predictors. The developed nomogram provides an effective screening tool, while the identified high-risk thresholds (APRI≥10.27, FIB-4≥19.03) offer valuable clinical warning indicators, enabling improved early diagnosis and intervention strategies for EGVB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.